CHICAGO & DUBLIN--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the availability in the United States of its Glucagon Emergency Kit, an FDA-approved and cost-effective alternative to treat severe ...

SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc. ® is pleased to announce the commercial launch and availability of Gvoke VialDx™ (glucagon injection). Gvoke VialDx (glucagon ...

The Food and Drug Administration as approved the first generic of a drug used to treat severe hypoglycemia. The agency has approved a generic glucagon for injection, 1 mg, from Amphastar ...

Gvoke (glucagon) is a prescription drug that’s used to treat severely low blood sugar in certain people with diabetes. Gvoke comes as a liquid solution that’s given as an injection under the skin.

Glucagon is indicated for the treatment of severe hypoglycemia in patients with diabetes mellitus and as a diagnostic aid for use during certain radiologic examinations. Lupin is introducing glucagon ...

Baqsimi (glucagon) is a prescription drug that’s used to help treat emergency episodes of low blood sugar in adults and some children with diabetes. Baqsimi comes as a powder for nasal inhalation.

Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low blood ...

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an ...

First concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch ...